...and more. MSC and ABIVERTINIB have a bright future outside of Covid-19. You have to get on the field of play first to show what you got and hopefully this will happen in H2 this year. thank God Sorrento has COVISTIX even though many have underestimated its importance to the company and investors. maybe we will see approvals in China or Korea before the FDA in the US. We should think about it and put up our top picks for 2022, 2023 and 2024.
I believe this will be Sorrento's first $$Billion-dollar year and that Scilex is up next for this year, I would sure like a EUA for ABIVERTINIB or MDC before that, or...what is your thought?
News 
Market Data 
Discover 
